Correction to “B‐cell Maturation Antigen‐Based Therapies Post‐Talquetamab in Relapsed or Refractory Multiple Myeloma”

Documenti analoghi

• Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
  di: Barry Paul, et al.
  Pubblicazione: (2025)
• European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing
  di: María‐Victoria Mateos, et al.
  Pubblicazione: (2026)
• Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions
  di: Kelley Julian, et al.
  Pubblicazione: (2026)
• Epcoritamab for Relapsed/Refractory EBV+ Post‐Transplant Lymphoproliferative Disorder of DLBCL‐Type
  di: Li Yuan Chan, et al.
  Pubblicazione: (2025)
• Early Free Light‐Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA‐Directed CAR‐T Cells
  di: Tim Richardson, et al.
  Pubblicazione: (2025)